Ireland’s HSE agrees to fund Skyclarys after Biogen improves commercial offer

The reimbursement decision clears the way for Irish patients with Friedreich’s ataxia to access the first treatment for the rare neurological disease, following prolonged negotiations over cost and clinical value.

Ireland’s Health Service Executive (HSE) has approved reimbursement of Biogen’s Skyclarys (omaveloxolone) for people with Friedreich’s ataxia, reversing an earlier recommendation against public funding after Biogen submitted a substantially improved commercial offer.

The final negotiated price remains confidential, but the decision follows a two-year access campaign and previous concerns that the medicine was not cost-effective at its proposed price.

Field	Content
Alert Type	Industry Update
Topic	Drug reimbursement; Market access
Organisation(s)	Health Service Executive (HSE); Biogen; National Centre for Pharmacoeconomics (NCPE)
Affected Stakeholders	People with Friedreich’s ataxia; neurologists; rare disease specialists; Irish healthcare system
Therapy Area(s)	Neurology; Rare disease
Geography	Ireland
What Happened	On 25 August 2026, the HSE approved reimbursement of Skyclarys (omaveloxolone) for people with Friedreich’s ataxia. The decision followed a substantially revised commercial proposal from Biogen that the HSE described as very different from the offer previously considered by its Drugs Group. The final price is commercially confidential. Health Minister Jennifer Carroll MacNeill asked the HSE to begin working with Biogen immediately to establish the process through which eligible patients can access treatment. (RTÉ)
Why It Matters	Skyclarys is the first treatment for Friedreich’s ataxia, a rare progressive neuromuscular disease affecting an estimated 200 people in Ireland. The reimbursement decision therefore moves the medicine from regulatory approval to publicly funded access for Irish patients, illustrating the separate roles played by marketing authorisation and national pricing and reimbursement decisions. (RTÉ)
Supporting Context	The decision represents a significant reversal in the medicine’s Irish reimbursement process. In December 2025, the NCPE recommended against reimbursement unless the price was reduced, and the HSE Drugs Group subsequently recommended against funding. Earlier estimates placed treatment at around €280,000 per patient annually, with a five-year budget impact of more than €130 million. Biogen subsequently made a substantially improved financial offer, although the final negotiated figure has not been disclosed. (RTÉ)
Who Is Most Affected	People living with Friedreich’s ataxia in Ireland are the immediate beneficiaries. Patients and families had campaigned for access for around two years, arguing that delays were particularly significant for a progressive disease in which lost neurological function may not be recoverable. (RTÉ)
Industry Impact	The case highlights the market-access challenge surrounding high-cost medicines for small rare-disease populations. It also demonstrates how confidential price negotiations can alter a reimbursement outcome even after an initial negative health-economic assessment, while prompting wider debate in Ireland about the speed of its reimbursement pathway for orphan medicines. (RTÉ)
Key Takeaway	HSE reimbursement turns Skyclarys’ existing regulatory approval into a route to funded patient access in Ireland after Biogen substantially improved its commercial offer.
What to Watch	The timing and eligibility arrangements for patient access are now the immediate next steps, with the HSE and Biogen expected to work together to make treatment available as quickly as possible. (RTÉ)
Primary Source	RTÉ News – HSE reimbursement decision
Relevant Date	25 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com